Skip to content

Evaluation of Mean Platelet Volume and Systemic Inflammatory Response Index (SIRI) in Patients of Acute Coronary Syndrome

Evaluation of Mean Platelet Volume and Systemic Inflammatory Response Index (SIRI) in Patients of Acute Coronary Syndrome

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07149883
Enrollment
300
Registered
2025-09-02
Start date
2025-09-20
Completion date
2026-10-20
Last updated
2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

To assess the diagnostic and prognostic significance of MPV and SIRI in patients presenting with acute coronary syndrome.(STEMI/NSTEMI/UN STABLE ANGINA)

Detailed description

Acute coronary syndrome (ACS), which includes unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI), is a leading cause of hospitalization and death globally【1】. The pathophysiology of ACS involves plaque rupture, platelet activation, thrombus formation, and a significant inflammatory component【2】. Early diagnosis and accurate risk stratification are critical for improving patient outcomes and guiding therapy. Mean Platelet Volume (MPV) is a simple, cost-effective parameter obtained from the complete blood count. It reflects platelet size and activity-larger platelets are more reactive and thrombogenic. Studies have demonstrated that MPV is elevated in patients with ACS and may correlate with infarct size and poor prognosis【3,4】. The systemic inflammatory response plays a pivotal role in the destabilization of atherosclerotic plaques. Recently, novel inflammatory indices such as the Systemic Inflammatory Response Index (SIRI)-calculated as (neutrophil count × monocyte count) / lymphocyte count-have emerged as potential marker for cardiovascular risk. SIRI reflects the combined effect of pro-inflammatory and anti-inflammatory components of the immune system【5】. Elevated SIRI has been associated with adverse outcomes in various conditions, including stroke, cancer, and cardiovascular diseases【6,7】. Despite the individual significance of MPV and SIRI, limited data are available on their combined utility in ACS patients. Evaluating both markers together may provide a more comprehensive picture of the thrombo-inflammatory state and help identify high-risk patients at admission, facilitating more personalized care【8】.

Interventions

OTHERComplete blood count

Complete blood count

DEVICEECHO

device that used to evaluate the cardiac function

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients ≥ 18 years old. * Diagnosed with acute coronary syndrome (unstable angina, NSTEMI, STEMI). * Admission within 24 hours of symptom onset.

Exclusion criteria

* o Active infection or chronic inflammatory diseases. * Known hematological disorders or malignancy. * Chronic liver or renal failure. * Recent surgery or trauma (\< 1 month). * Patients with rheumatic heart disease * Patient refusal

Design outcomes

Primary

MeasureTime frameDescription
To assess the diagnostic and prognostic significance of MPV and SIRI in patients presenting with acute coronary syndrome.(STEMI/NSTEMI/UN STABLE ANGINA)BaselineEvaluation of mean platelet volume and systemic inflammatory response index (SIRI) in patients of acute coronary syndrome

Secondary

MeasureTime frameDescription
To assess the diagnostic and prognostic significance of MPV and SIRI in patients presenting with acute coronary syndrome.(STEMI/NSTEMI/UN STABLE ANGINABaselineEvaluation of mean platelet volume and systemic inflammatory response index (SIRI) in patients of acute coronary syndrome

Contacts

Primary ContactAsmaa Salama ahmed omar, Resident doctor
asmaasalamaahmed4@gmail.com+01067687469

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026